When Mounjaro is stopped, nothing happens overnight. Tirzepatide's elimination half-life is about five to six days, so the amount in the body roughly halves every five or six days and the effect fades over the following weeks rather than the following day (US label, EU SmPC). What follows over the next year was measured in SURMOUNT-4: adults switched abruptly to placebo after 36 weeks on tirzepatide, with no taper, regained 14.0% of body weight over the following year, on average (Aronne 2024); individual results vary. At GetLean the exit is planned from the first consultation, and Dr Quek steps the dose down at the monthly reviews rather than stopping it at once. This article walks through the first weeks, the first months and the first year, and what the label and trials show.
Availability in Singapore. This medicine is registered with Singapore's Health Sciences Authority, and its registered indication includes weight management. Which medicine suits a particular person, if any does, is decided by the doctor who assesses them.
What the labels and SURMOUNT-4 report about how tirzepatide clears, what it does while it is in the body, and the first year after it is stopped.
| Stage | What the label or trial reports | Source |
|---|---|---|
| Weeks one to four | An elimination half-life of about five days (EU label) or five to six days (US label), so the amount in the body roughly halves every five or six days | EU SmPC, US label |
| While the medicine is in the body | Tirzepatide reduces calorie intake, an effect "likely mediated by affecting appetite" | US label |
| The first year | In SURMOUNT-4, adults who lost 20.9% over 36 weeks and were then switched abruptly to placebo, with no taper, regained 14.0% of body weight from week 36 to week 88 and finished still 9.9% below their starting weight, on average | Aronne 2024 |
Weeks one to four: the medicine leaves the body
Slowly, because it was designed to last a week.
The European label gives tirzepatide an elimination half-life of approximately five days, and the United States label five to six days in people with overweight or obesity (EU SmPC, US label). Each half-life halves what is left. The European label's pregnancy advice reflects how long that takes: it says to stop tirzepatide at least one month before a planned pregnancy because of the long half-life (EU SmPC).
So the first missed weekly dose does not switch anything off. Its effect tapers on its own over the weeks that follow, which is part of why some people notice little change at first.
Appetite in the weeks after the last dose
The label says tirzepatide reduces calorie intake, an effect "likely mediated by affecting appetite" (US label). As the medicine leaves, that effect fades over the following weeks. That is why the eating pattern and the training habit are built while the medication is still working, rather than after it has gone. Appetite after stopping GLP-1 goes into more detail.
Side effects
Nausea, vomiting and the other stomach side effects are mostly a feature of starting and of dose increases; in SURMOUNT-MAINTAIN, gastrointestinal events mostly occurred during dose escalation (Horn 2026). Neither label nor any trial we found describes what happens to them after stopping, so we will not guess. The withdrawal-symptom question is covered in Mounjaro and Wegovy withdrawal symptoms.
The first year: what SURMOUNT-4 found
When tirzepatide was stopped abruptly, with no taper, much of the weight came back, but not all of it.
SURMOUNT-4 gave adults tirzepatide for 36 weeks, during which they lost 20.9% of body weight on average. Those then randomised to placebo were switched abruptly, with no taper. Over the following year, from week 36 to week 88, that group regained 14.0% of body weight, and it finished still 9.9% below its starting weight (Aronne 2024).
Those are averages in a studied population, and individual results vary. The regain article covers what the averages hide.
Stepping down rather than stopping
The labels give no instruction on tapering when stopping (US label), and every withdrawal trial stopped treatment outright, with no taper. At GetLean we favour a gradual reduction under a doctor's guidance rather than a cliff-edge stop, which allows appetite to adjust incrementally: Dr Quek steps the dose down at the monthly reviews, towards the lowest effective dose, as the response comes in. Stepping down is a different picture from stopping: in SURMOUNT-MAINTAIN, adults who stepped down to a lower dose of tirzepatide after 60 weeks were still 16.6% below their starting weight a year later (Horn 2026). Mounjaro or Wegovy maintenance dose sets out that trial, and weaning off GLP-1 how a planned taper works.
What makes coming off go better
Building what replaces the medicine before the medicine goes. In the trials above, tirzepatide was stopped on a date, with no taper. A planned exit is built the other way round: muscle protected with resistance training, an eating pattern that no longer needs effort, and a weighing habit already running before the last dose. While appetite is quiet, the daily WhatsApp coaching builds the eating pattern and the training habit. Designed to end: planning a GLP-1 exit sets out what that plan contains.
Exercise also counts after the medication stops. In a Copenhagen randomised trial that followed adults for a year after treatment ended, those who had combined a GLP-1 medication with supervised exercise were more likely than those who had taken the medication alone to still hold a loss of at least 10% of their starting weight (Jensen 2024). The medication was liraglutide, an earlier GLP-1 medicine, and the initial loss came from a low-calorie diet.
At GetLean, the programme is designed to end: our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. The taper is planned from the first consultation and set at the monthly reviews as the response comes in.
Individual results vary, and clinical-trial figures describe the populations studied. Never stop or change a prescribed medicine on your own; that is a conversation with the doctor who prescribed it.
What happens after the taper at GetLean?
Finishing the taper does not have to end the support. After the taper, a patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time: a restart begins with a review consultation, and whether to restart the medication is his decision at that review.
Designed to end: a programme whose pace and taper off the medication are planned from the first consult, so the result holds after the medication stops.
Common questions
How long does Mounjaro stay in your system after stopping?
Tirzepatide's elimination half-life is about five days in the EU label and five to six days in the US label, so the amount in the body roughly halves every five or six days (EU SmPC, US label). Because of that long half-life, the EU label says to stop at least one month before a planned pregnancy.
How much weight comes back after stopping Mounjaro?
In SURMOUNT-4, adults who had lost 20.9% over 36 weeks and were then switched abruptly to placebo, with no taper, regained 14.0% of body weight over the next year, finishing 9.9% below where they started (Aronne 2024). Individual results vary.
Do you need to taper Mounjaro?
The labels give no taper instruction, and the withdrawal trials stopped treatment outright, with no taper. At GetLean the dose is stepped down at Dr Quek's monthly reviews rather than stopped overnight, so appetite can adjust step by step. In SURMOUNT-MAINTAIN, adults who stepped down to a lower dose of tirzepatide after 60 weeks were still 16.6% below their starting weight a year later (Horn 2026). Any change is a decision for the prescribing doctor.
When does appetite come back after stopping Mounjaro?
Over weeks rather than days. The label says tirzepatide lowers calorie intake through appetite, and its half-life is about five to six days (US label), so the appetite effect fades as the medicine leaves the body. The eating pattern and the training habit are built while the medication is still working, so they are in place before that effect has gone.
What happens after the taper at GetLean?
A patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time; a restart begins with a review consultation, and whether to restart the medication is his decision.